According to the latest study titled ‘Global Antifungal Drugs Market: Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, China, Japan, India)’ available at MarketStudyReport.com, the global antifungal drugs market is estimated to grow with a CAGR of 3.70% through the year 2023.
 

Antifungal drug is a pharmaceutical fungicide used to cure and prevent fungal infections such as athlete’s foot, candidiasis, ringworm, and other serious systemic infections. Factors such as rising occurrence of fungal infections, awareness of over-the-counter drugs, along with availability of innovative antifungals is driving the growth of antifungal drugs market.
 

Though, increasing geriatric population, rising medical expenditure, and supportive initiatives by government will continue to augment the industry, but, surging presence of generic versions of antifungal drugs, patent expiration of innovator drugs as well as increasing prevalence of fungal resistance, and concerns regarding counterfeit drugs will restrain the growth of antifungal drugs market.
 

The study encompasses details about segmental shares, and expansion strategies adopted by manufacturers. It also provides, insight about the challenges, drivers, trends, and restraints impacting the market growth.
 

Based on drug type, the antifungal drugs market is segmented into polyenes, echinocandins, azole, and other class antifungal drugs. While speaking of therapeutic indications, the industry is split into aspergillus, dermatophytosis, candidiasis, and other therapeutic indications. 
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1550842/
 

Considering the geographical landscape, the antifungal drugs market is fragmented into four major regions which are Europe, North America, APAC, and rest of the world. North America antifungal drugs market registered the largest regional share in 2017, pertaining to expanding patient base and advanced medical infrastructure, claims the report.
 

Leading players in the antifungal drugs market are GlaxoSmithKline, Merck & Co., Sanofi, Astellas Pharma, Bayer, Abbott Laboratories, Novartis International AG, Pfizer, and Kramer Laboratories.